Standardizing Statistical Thresholds in Pilot Trials

Given the fixed 20% Phase III budget and the tradeoff between costly false positives and discarded breakthroughs, a rigid uniform threshold (A) ignores domain risk differences, while unstructured qualitative review (C) reintroduces the flexibility that caused ...

Given the fixed 20% budget cap and the explicit tradeoff between costly false positives and missed breakthroughs, a single rigid threshold either wastes funds on noise (if lenient) or discards high-potential novel treatments (if strict). A tiered approach dire...

Tiered standards directly address the tradeoff by calibrating risk tolerance to innovation type—loosening thresholds for genuinely novel mechanisms where Type II errors (missing breakthroughs) are costlier, while tightening them for incremental drugs where Typ...

Tiered standards (B) directly address the tradeoff by calibrating risk tolerance to innovation type—allowing more Type II error protection (avoiding discarding breakthroughs) for first-in-class mechanisms while tightening Type I error control for incremental d...

Given the fixed 20% budget cap and the explicit tradeoff between Type I and Type II errors, a uniform frequentist cutoff (A) ignores that innovation potential varies, while purely qualitative (C) or replication-heavy (D) approaches either invite subjectivity/p...

Given the fixed 20% Phase III budget and the need to balance Type I vs Type II errors across heterogeneous domains, a single rigid threshold (A) or reviewer-dependent judgment (C) either risks discarding breakthroughs or reintroduces subjective p-hacking. Opti...

Given the fixed 20% budget cap and the explicit tension between Type I/II errors, the policy needs a mechanism that adapts rigor to context rather than a single blunt cutoff—rigid p<0.05 (A) risks discarding breakthroughs, while removing thresholds (C) invites...

Given the fixed budget cap (20%) and the risk of both false positives (wasting Phase III funds) and false negatives (discarding breakthroughs), a rigid p<0.05 rule (A) risks Type II errors on genuinely novel treatments, while purely qualitative approaches (C) ...

The key issue is choosing a rule that is standardized, reduces flexibility that enables p-hacking, and respects the limited budget by controlling false positives. A rigid frequentist threshold is the clearest way to keep decision-making uniform across trials, ...

The key issue is that a fixed, universal p-value cutoff is meant to reduce inconsistent decision-making and limit p-hacking, which is especially important when only 20% of pilots can advance. Among the options, the rigid standard best matches that goal by enfo...

The key issue is to keep the rule simple and consistent enough to reduce p-hacking, while still controlling the number of pilots that advance given the strict 20% Phase III budget. A rigid, uniform p-value threshold is the most standardizable way to limit fals...

A fixed policy is needed because the consortium wants to reduce flexibility that encourages p-hacking, while also controlling how many pilots can advance under a tight Phase III budget. A strict uniform threshold gives the clearest, most standardized stop/go r...

To standardize stop/go decisions under a fixed budget, the policy should be consistent, transparent, and resistant to p-hacking while still protecting against wasting Phase III resources. A rigid frequentist cutoff is the clearest way to reduce false positives...

The key constraint is that the consortium wants a standard policy that reduces flexible thresholding and p-hacking, while also respecting a limited Phase III budget and controlling false positives. A rigid, uniform p < 0.05 rule is the clearest way to standard...

A rigid p < 0.05 rule best matches the consortium’s need for a simple, consistent stop/go policy that limits false positives and reduces p-hacking. Since the budget can only support 20% advancing, a uniform threshold is the clearest way to keep the pipeline se...

The best choice is the one that reduces arbitrary threshold flexibility while still keeping a consistent rule for moving only the strongest pilots forward. A rigid p < 0.05 standard is simple, transparent, and helps limit p-hacking and false positives, which i...

This decision requires balancing the risk of discarding breakthroughs (Type II error) with the need to manage a limited budget (Type I error) and prevent p-hacking. Option (E) provides the most objective and sophisticated solution by incorporating prior data a...

Option (E) provides the most robust solution by integrating prior knowledge and effect sizes into a "Probability of Success" score, which directly addresses the budget constraint by ranking potential investments. This framework mitigates "p-hacking" by moving ...

To maximize funding efficiency while minimizing the loss of breakthroughs, the framework must balance the risk of false negatives (Type II errors) with the potential for "p-hacking." **Option (E)** is the most robust solution because it incorporates prior know...

The problem requires balancing the protection of a limited Phase III budget (reducing false positives) against the risk of discarding breakthroughs (reducing false negatives) while preventing "p-hacking." Option (E) addresses these needs by replacing rigid, ma...

The decision requires balancing the risk of discarding breakthroughs (Type II error) with the need to efficiently allocate a fixed budget by avoiding failed large-scale trials (Type I error). Option (E) provides the most robust solution by integrating prior do...

This decision requires balancing the risk of abandoning breakthroughs (Type II error) with the fiscal reality of a limited Phase III budget. Option (E) provides a systematic framework that incorporates prior knowledge and clinical probability, moving beyond bi...

To balance the efficient use of limited funding (20% conversion rate) with the protection of high-potential breakthroughs, the consortium needs a system that integrates effect size, prior evidence, and clinical risk. Option (E) provides a mathematically rigoro...

This challenge requires balancing the risk of false negatives for breakthroughs (Type II error) with the fiscal necessity of preventing false positives (Type I error) and mitigating "p-hacking." Option (E) addresses these constraints by replacing binary p-valu...